Cargando…

A new cognitive evaluation battery for Down syndrome and its relevance for clinical trials

The recent prospect of pharmaceutical interventions for cognitive impairment of Down syndrome (DS) has boosted a number of clinical trials in this population. However, running the trials has raised some methodological challenges and questioned the prevailing methodology used to evaluate cognitive fu...

Descripción completa

Detalles Bibliográficos
Autores principales: de Sola, Susana, de la Torre, Rafael, Sánchez-Benavides, Gonzalo, Benejam, Bessy, Cuenca-Royo, Aida, del Hoyo, Laura, Rodríguez, Joan, Catuara-Solarz, Silvina, Sanchez-Gutierrez, Judit, Dueñas-Espin, Ivan, Hernandez, Gimena, Peña-Casanova, Jordi, Langohr, Klaus, Videla, Sebastia, Blehaut, Henry, Farre, Magi, Dierssen, Mara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4455308/
https://www.ncbi.nlm.nih.gov/pubmed/26089807
http://dx.doi.org/10.3389/fpsyg.2015.00708
_version_ 1782374741409005568
author de Sola, Susana
de la Torre, Rafael
Sánchez-Benavides, Gonzalo
Benejam, Bessy
Cuenca-Royo, Aida
del Hoyo, Laura
Rodríguez, Joan
Catuara-Solarz, Silvina
Sanchez-Gutierrez, Judit
Dueñas-Espin, Ivan
Hernandez, Gimena
Peña-Casanova, Jordi
Langohr, Klaus
Videla, Sebastia
Blehaut, Henry
Farre, Magi
Dierssen, Mara
author_facet de Sola, Susana
de la Torre, Rafael
Sánchez-Benavides, Gonzalo
Benejam, Bessy
Cuenca-Royo, Aida
del Hoyo, Laura
Rodríguez, Joan
Catuara-Solarz, Silvina
Sanchez-Gutierrez, Judit
Dueñas-Espin, Ivan
Hernandez, Gimena
Peña-Casanova, Jordi
Langohr, Klaus
Videla, Sebastia
Blehaut, Henry
Farre, Magi
Dierssen, Mara
author_sort de Sola, Susana
collection PubMed
description The recent prospect of pharmaceutical interventions for cognitive impairment of Down syndrome (DS) has boosted a number of clinical trials in this population. However, running the trials has raised some methodological challenges and questioned the prevailing methodology used to evaluate cognitive functioning of DS individuals. This is usually achieved by comparing DS individuals to matched healthy controls of the same mental age. We propose a new tool, the TESDAD Battery that uses comparison with age-matched typically developed adults. This is an advantageous method for probing the clinical efficacy of DS therapies, allowing the interpretation and prediction of functional outcomes in clinical trials. In our DS population the TESDAD battery permitted a quantitative assessment of cognitive defects, which indicated language dysfunction and deficits in executive function, as the most important contributors to other cognitive and adaptive behavior outcomes as predictors of functional change in DS. Concretely, auditory comprehension and functional academics showed the highest potential as end-point measures of therapeutic intervention for clinical trials: the former as a cognitive key target for therapeutic intervention, and the latter as a primary functional outcome measure of clinical efficacy. Our results also emphasize the need to explore the modulating effects of IQ, gender and age on cognitive enhancing treatments. Noticeably, women performed significantly better than men of the same age and IQ in most cognitive tests, with the most consistent differences occurring in memory and executive functioning and negative trends rarely emerged on quality of life linked to the effect of age after adjusting for IQ and gender. In sum, the TESDAD battery is a useful neurocognitive tool for probing the clinical efficacy of experimental therapies in interventional studies in the DS population suggesting that age-matched controls are advantageous for determining normalization of DS.
format Online
Article
Text
id pubmed-4455308
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-44553082015-06-18 A new cognitive evaluation battery for Down syndrome and its relevance for clinical trials de Sola, Susana de la Torre, Rafael Sánchez-Benavides, Gonzalo Benejam, Bessy Cuenca-Royo, Aida del Hoyo, Laura Rodríguez, Joan Catuara-Solarz, Silvina Sanchez-Gutierrez, Judit Dueñas-Espin, Ivan Hernandez, Gimena Peña-Casanova, Jordi Langohr, Klaus Videla, Sebastia Blehaut, Henry Farre, Magi Dierssen, Mara Front Psychol Psychology The recent prospect of pharmaceutical interventions for cognitive impairment of Down syndrome (DS) has boosted a number of clinical trials in this population. However, running the trials has raised some methodological challenges and questioned the prevailing methodology used to evaluate cognitive functioning of DS individuals. This is usually achieved by comparing DS individuals to matched healthy controls of the same mental age. We propose a new tool, the TESDAD Battery that uses comparison with age-matched typically developed adults. This is an advantageous method for probing the clinical efficacy of DS therapies, allowing the interpretation and prediction of functional outcomes in clinical trials. In our DS population the TESDAD battery permitted a quantitative assessment of cognitive defects, which indicated language dysfunction and deficits in executive function, as the most important contributors to other cognitive and adaptive behavior outcomes as predictors of functional change in DS. Concretely, auditory comprehension and functional academics showed the highest potential as end-point measures of therapeutic intervention for clinical trials: the former as a cognitive key target for therapeutic intervention, and the latter as a primary functional outcome measure of clinical efficacy. Our results also emphasize the need to explore the modulating effects of IQ, gender and age on cognitive enhancing treatments. Noticeably, women performed significantly better than men of the same age and IQ in most cognitive tests, with the most consistent differences occurring in memory and executive functioning and negative trends rarely emerged on quality of life linked to the effect of age after adjusting for IQ and gender. In sum, the TESDAD battery is a useful neurocognitive tool for probing the clinical efficacy of experimental therapies in interventional studies in the DS population suggesting that age-matched controls are advantageous for determining normalization of DS. Frontiers Media S.A. 2015-06-04 /pmc/articles/PMC4455308/ /pubmed/26089807 http://dx.doi.org/10.3389/fpsyg.2015.00708 Text en Copyright © 2015 de Sola, de la Torre, Sánchez-Benavides, Benejam, Cuenca-Royo, del Hoyo, Rodríguez, Catuara-Solarz, Sanchez-Gutierrez, Dueñas-Espin, Hernandez, Peña-Casanova, Langohr, Videla, Blehaut, Farre, Dierssen and The TESDAD Study Group. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Psychology
de Sola, Susana
de la Torre, Rafael
Sánchez-Benavides, Gonzalo
Benejam, Bessy
Cuenca-Royo, Aida
del Hoyo, Laura
Rodríguez, Joan
Catuara-Solarz, Silvina
Sanchez-Gutierrez, Judit
Dueñas-Espin, Ivan
Hernandez, Gimena
Peña-Casanova, Jordi
Langohr, Klaus
Videla, Sebastia
Blehaut, Henry
Farre, Magi
Dierssen, Mara
A new cognitive evaluation battery for Down syndrome and its relevance for clinical trials
title A new cognitive evaluation battery for Down syndrome and its relevance for clinical trials
title_full A new cognitive evaluation battery for Down syndrome and its relevance for clinical trials
title_fullStr A new cognitive evaluation battery for Down syndrome and its relevance for clinical trials
title_full_unstemmed A new cognitive evaluation battery for Down syndrome and its relevance for clinical trials
title_short A new cognitive evaluation battery for Down syndrome and its relevance for clinical trials
title_sort new cognitive evaluation battery for down syndrome and its relevance for clinical trials
topic Psychology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4455308/
https://www.ncbi.nlm.nih.gov/pubmed/26089807
http://dx.doi.org/10.3389/fpsyg.2015.00708
work_keys_str_mv AT desolasusana anewcognitiveevaluationbatteryfordownsyndromeanditsrelevanceforclinicaltrials
AT delatorrerafael anewcognitiveevaluationbatteryfordownsyndromeanditsrelevanceforclinicaltrials
AT sanchezbenavidesgonzalo anewcognitiveevaluationbatteryfordownsyndromeanditsrelevanceforclinicaltrials
AT benejambessy anewcognitiveevaluationbatteryfordownsyndromeanditsrelevanceforclinicaltrials
AT cuencaroyoaida anewcognitiveevaluationbatteryfordownsyndromeanditsrelevanceforclinicaltrials
AT delhoyolaura anewcognitiveevaluationbatteryfordownsyndromeanditsrelevanceforclinicaltrials
AT rodriguezjoan anewcognitiveevaluationbatteryfordownsyndromeanditsrelevanceforclinicaltrials
AT catuarasolarzsilvina anewcognitiveevaluationbatteryfordownsyndromeanditsrelevanceforclinicaltrials
AT sanchezgutierrezjudit anewcognitiveevaluationbatteryfordownsyndromeanditsrelevanceforclinicaltrials
AT duenasespinivan anewcognitiveevaluationbatteryfordownsyndromeanditsrelevanceforclinicaltrials
AT hernandezgimena anewcognitiveevaluationbatteryfordownsyndromeanditsrelevanceforclinicaltrials
AT penacasanovajordi anewcognitiveevaluationbatteryfordownsyndromeanditsrelevanceforclinicaltrials
AT langohrklaus anewcognitiveevaluationbatteryfordownsyndromeanditsrelevanceforclinicaltrials
AT videlasebastia anewcognitiveevaluationbatteryfordownsyndromeanditsrelevanceforclinicaltrials
AT blehauthenry anewcognitiveevaluationbatteryfordownsyndromeanditsrelevanceforclinicaltrials
AT farremagi anewcognitiveevaluationbatteryfordownsyndromeanditsrelevanceforclinicaltrials
AT dierssenmara anewcognitiveevaluationbatteryfordownsyndromeanditsrelevanceforclinicaltrials
AT anewcognitiveevaluationbatteryfordownsyndromeanditsrelevanceforclinicaltrials
AT desolasusana newcognitiveevaluationbatteryfordownsyndromeanditsrelevanceforclinicaltrials
AT delatorrerafael newcognitiveevaluationbatteryfordownsyndromeanditsrelevanceforclinicaltrials
AT sanchezbenavidesgonzalo newcognitiveevaluationbatteryfordownsyndromeanditsrelevanceforclinicaltrials
AT benejambessy newcognitiveevaluationbatteryfordownsyndromeanditsrelevanceforclinicaltrials
AT cuencaroyoaida newcognitiveevaluationbatteryfordownsyndromeanditsrelevanceforclinicaltrials
AT delhoyolaura newcognitiveevaluationbatteryfordownsyndromeanditsrelevanceforclinicaltrials
AT rodriguezjoan newcognitiveevaluationbatteryfordownsyndromeanditsrelevanceforclinicaltrials
AT catuarasolarzsilvina newcognitiveevaluationbatteryfordownsyndromeanditsrelevanceforclinicaltrials
AT sanchezgutierrezjudit newcognitiveevaluationbatteryfordownsyndromeanditsrelevanceforclinicaltrials
AT duenasespinivan newcognitiveevaluationbatteryfordownsyndromeanditsrelevanceforclinicaltrials
AT hernandezgimena newcognitiveevaluationbatteryfordownsyndromeanditsrelevanceforclinicaltrials
AT penacasanovajordi newcognitiveevaluationbatteryfordownsyndromeanditsrelevanceforclinicaltrials
AT langohrklaus newcognitiveevaluationbatteryfordownsyndromeanditsrelevanceforclinicaltrials
AT videlasebastia newcognitiveevaluationbatteryfordownsyndromeanditsrelevanceforclinicaltrials
AT blehauthenry newcognitiveevaluationbatteryfordownsyndromeanditsrelevanceforclinicaltrials
AT farremagi newcognitiveevaluationbatteryfordownsyndromeanditsrelevanceforclinicaltrials
AT dierssenmara newcognitiveevaluationbatteryfordownsyndromeanditsrelevanceforclinicaltrials
AT newcognitiveevaluationbatteryfordownsyndromeanditsrelevanceforclinicaltrials